Site Editor

David S. Ettinger, MD, FACP, FCCP


AACR 2022: Overall Survival Update With Sotorasib in KRAS-Mutated Lung Cancer

By: Joseph Fanelli
Posted: Thursday, April 28, 2022

For patients with non–small cell lung cancer (NSCLC) who did not respond to previous lines of therapy, treatment with the KRAS G12C inhibitor sotorasib continued to demonstrate both safety and efficacy in the phase I/II CodeBreaK 100 trial. Grace K. Dy, MD, of the Roswell Park Comprehensive Cancer Center, Buffalo, New York, and colleagues reported that patients treated with the KRAS G12C inhibitor had a 2-year overall survival rate of 32.5%, based on the findings presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract CT008).

“The survival outcomes and toxicity profile make sotorasib the treatment of choice compared to salvage chemotherapy in patients who did not respond to previous therapies,” said Dr. Dy in an institutional press release. “Our findings also provide rationale for studies that investigate the incorporation of sotorasib earlier in the treatment course to improve the outcomes for NSCLC patients who are less likely to benefit from immunotherapy.”

In this updated analysis, the authors focused on the enrolled 174 patients with locally advanced or metastatic NSCLC whose tumors harbored the KRAS G12C mutation and who received prior therapies. The patients were treated with 960 mg/day of sotorasib. Most subjects had received an average of two prior lines of therapy, including anti–PD-1 or anti–PD-L1 immunotherapy and platinum-based chemotherapy.

Among the patients, 40.7% experienced a partial or complete response to treatment with sotorasib, with a median duration of response of 12.3 months. Patients exhibited a median progression-free survival of 6.3 months and an overall survival of 12.5 months. After 1 year of treatment, patients had a 50.8% overall survival rate, and it was 32.5% after 2 years. An additional analysis of both blood and tumor samples discovered a prolonged clinical benefit for patients treated with sotorasib, regardless of tumor mutation burden, PD-L1 expression, or STK11 co-mutation status

Disclosure: For a full disclosure of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.